BACTRIM (sulfamethoxazole; trimethoprim) by PharmaIN is clinical pharmacology bactrim is rapidly absorbed following oral administration. First approved in 1975.
Drug data last refreshed 20h ago · AI intelligence enriched 2w ago
Bactrim is a fixed-dose combination of sulfamethoxazole and trimethoprim, two synergistic antibacterial agents that inhibit sequential steps in bacterial folate synthesis. It is rapidly absorbed orally and achieves therapeutic concentrations in blood and tissue within 1-4 hours, with a mean serum half-life of 8-10 hours for trimethoprim and 10 hours for sulfamethoxazole. Bactrim is indicated for a broad spectrum of bacterial infections including urinary tract infections, Pneumocystis jirovecii pneumonia, and other susceptible gram-positive and gram-negative infections.
Bactrim is approaching loss of exclusivity with minimal Part D spending ($2K in 2023) and only 28 claims, indicating a mature, low-volume legacy product with a contracting brand team.
CLINICAL PHARMACOLOGY BACTRIM is rapidly absorbed following oral administration. Both sulfamethoxazole and trimethoprim exist in the blood as unbound, protein-bound and metabolized forms; sulfamethoxazole also exists as the conjugated form. Sulfamethoxazole is metabolized in humans to at least 5…
Worked on BACTRIM at PharmaIN? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
A Non-Interventional Safety Study of Balsamic Bactrim
A Safety Study of Balsamic Bactrim in Pediatric Participants With Acute Bronchitis
Upgrade to Pro to access Medicare Part D spending data and other premium pharma intelligence.
Upgrade to Pro — $25/moWorking on Bactrim offers stability in a mature, low-risk product but limited career acceleration; roles focus on operational efficiency, generic defense, and market maintenance rather than growth or innovation. This is a legacy product suitable for specialists seeking stable, predictable work rather than high-visibility launches or market expansion.